In 2013, the Vaccine Alliance has again assessed potential new priorities for its vaccine support programmes in the next five years. A landscape analysis, conducted by the World Health Organization (WHO), identified fifteen vaccines not yet in Gavi’s portfolio or in development with an anticipated licensure date by 2019. Each vaccine was evaluated to estimate the potential health impact, cost and value for money alongside additional strategic and programmatic considerations. The outcomes from this initial analysis have been summarised in vaccine ‘scorecards’.
With a view to prioritise vaccines providing good ‘value for money’ and with the highest impact on disease, the Gavi Board shortlisted five options for further evaluation: malaria vaccines, oral cholera vaccines, seasonal influenza vaccination for pregnant women, rabies vaccines (for post-exposure prophylaxis), and an investment in additional mass campaigns with yellow fever vaccines.
With input from over one hundred experts, Vaccine Alliance partners, in-country stakeholders and an Independent Expert Committee, Gavi undertook further, in depth analyses of these five options to inform investment recommendations. Detailed analyses for each of the five vaccines can be downloaded below.
At a meeting in Cambodia in November 2013, the Gavi Board reviewed the analyses and decided to:
Separately, the Gavi Board endorsed opening a window of support for inactivated poliovirus vaccine (IPV) for all countries benefitting from Gavi support.
Finally, the Board also took the decision to begin providing country support for a vaccine against Japanese encephalitis (JE). The decision to offer JE vaccine support was taken as part of the previous vaccine investment strategy, but a funding window could not be opened until a WHO prequalified product was available. In October, a Chinese manufacturer received WHO prequalification on its JE vaccine.
The next Vaccine Investment Strategy will be developed in 2018.